Vanda Pharmaceuticals Inc...
4.39
-0.14 (-3.09%)
At close: Jan 14, 2025, 3:59 PM
4.35
-0.91%
After-hours Jan 14, 2025, 06:01 PM EST
undefined%
Bid 4.35
Market Cap 255.97M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.29
PE Ratio (ttm) -15.14
Forward PE n/a
Analyst Buy
Ask 5.02
Volume 406,194
Avg. Volume (20D) 611,600
Open 4.55
Previous Close 4.53
Day's Range 4.35 - 4.55
52-Week Range 3.46 - 6.75
Beta undefined

About VNDA

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...

Industry Biotechnology
Sector Healthcare
IPO Date Apr 12, 2006
Employees 203
Stock Exchange NASDAQ
Ticker Symbol VNDA

Analyst Forecast

According to 2 analyst ratings, the average rating for VNDA stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 253.08% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Vanda Pharmaceuticals Inc. is scheduled to release its earnings on Feb 5, 2025, during market hours.
Analysts project revenue of $51.25M, reflecting a 13.21% YoY growth and earnings per share of -0.17, making a 325.00% increase YoY.
3 months ago · Source
+8.33%
Vanda Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
6 months ago · Source
-2.84%
Vanda Pharmaceuticals Inc. shares are trading lower after Future Pak withdrew its proposal to purchase the company.